BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
Over the past 16 months, Chinese-domiciled biotechnology companies have emerged as formidable forces in the global pharmaceutical landscape, featuring prominently…
Read More
The Non-GLP-1 Obesity Drug Market Set for Explosive 50-Fold Growth, Reaching $15.5 Billion by 2031
The global pharmaceutical market for obesity treatments is poised for a dramatic transformation, with a burgeoning segment of non-Glucagon-like peptide-1…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced an…
Read More
Insilico CEO Sees Potentially $2.75 Billion Collaboration as ‘Fusing Lilly’s Clinical Excellence’ with Insilico’s ‘End-to-End AI Engine’
On March 29, Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, announced a landmark collaboration with pharmaceutical giant Eli…
Read More
Jeito Capital’s Second Fund Closes Above Target, Bolstering European Biopharma Investment to Over €1.6 Billion
Global independent private equity fund Jeito Capital has achieved a significant milestone in European biopharma investment with the successful closure…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion, Bolstering Neuroscience Pipeline
Eli Lilly and Company announced a significant move to acquire Centessa Pharmaceuticals, a UK-based biopharmaceutical company specializing in neuroscience, in…
Read More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion to Bolster Immunology and Rare Disease Portfolio
Biogen, a global biotechnology company renowned for its pioneering work in neuroscience, has announced a significant strategic acquisition of Apellis…
Read More
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline
TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…
Read More
